Ex-CEO of devicemaker gets probation for lying about imports

A case that tested the FDA's authority over imported parts for medical device manufacturing is nearly complete with former Spectranetics ($SPNC) CEO John Schulte being sentenced to a year of probation and a $5,000 fine.

Schulte, who left the medical laser manufacturer in 2008 after a probe into the company's practices was initiated by the FDA and other authorities, was convicted of only one count of lying to federal investigators. He was acquitted, after a 5-week trial, of about a dozen other charges ranging from defrauding the government to smuggling unapproved medical devices into the country, reports The Colorado Springs Gazette. Schulte could have received up to three years in prison and a fines of up to $250,000. Prosecutors sought two years in jail and three years of probation.

The indictment alleges that Schulte and others imported unapproved devices and avoided FDA oversight. It said they concealed their actions not only from the FDA and the Department of Homeland Security, but also from internal investigators at Spectranetics.

Two other former Spectranetics executives, Trung Pham and Obinna Adighije, also had all federal charges dropped against them, according to the story. Hernan Ricuarte, a consultant to the company, pleaded guilty in August to participating in the alleged scheme by sending an email to a Spectranetics employee that suggested using bogus invoices for non-FDA approved catheter guidewires. Spectranetics itself settled the investigation in 2009 when it paid $5 million in penalties and forfeitures, according to the Gazette.

- read the Gazette story

Related Articles:
Former Spectranetics chief convicted of lying to federal investigators
Indictment: Former Spectranetics execs imported unapproved devices

Suggested Articles

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Continuing its expansion efforts, Japan’s Fujifilm will make a major investment in its U.S. gene therapy operation in Texas.